Status:

COMPLETED

Multimodal Diagnostic Assessment of Cerebral Gliomas With FET & FCH PET/CT, and Magnetic Resonance Imaging/Spectroscopy

Lead Sponsor:

University of Lausanne Hospitals

Collaborating Sponsors:

Lionel Perrier Foundation (Montreux, Switzerland)

Conditions:

Glioma

Eligibility:

All Genders

18+ years

Brief Summary

The aim of this study is to establish the diagnostic value of O-(2-\[18F\]-fluoroethyl)-L-tyrosine (FET) PET-CT, \[18F\]-fluorocholine (FCH) and magnetic resonance imaging (MRI) combined with magnetic...

Detailed Description

The objectives of the study are: * To demonstrate if the multimodal approach, combining the morphological aspect of the MRI with the metabolic aspect of the tumor with magnetic resonance spectroscopy...

Eligibility Criteria

Inclusion

  • Suspicion of intracerebral glioma on MR
  • Men of women
  • Age \>18, no upper limit as long as a biopsy or intervention is foreseen

Exclusion

  • Need of rapid intervention in \<2 weeks
  • Previous neurosurgical intervention (biopsy, shunt, etc.) or any other cerebral treatment

Key Trial Info

Start Date :

July 1 2009

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

January 1 2016

Estimated Enrollment :

51 Patients enrolled

Trial Details

Trial ID

NCT00939315

Start Date

July 1 2009

End Date

January 1 2016

Last Update

January 26 2016

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Centre Hospitalier Universitaire Vaudois

Lausanne, CH, Switzerland, 1011

Multimodal Diagnostic Assessment of Cerebral Gliomas With FET & FCH PET/CT, and Magnetic Resonance Imaging/Spectroscopy | DecenTrialz